A 12-week, Multicentre, Randomised, Double-blind, Double-dummy, 2-arm Parallel Group Study Comparing the Efficacy and Safety of Foster® 100/6 (Beclomethasone Dipropionate 100 µg Plus Formoterol 6 µg/Actuation), 2 Puffs b.i.d., Versus Symbicort® 200/6 (Budesonide 200 µg Plus Formoterol 6 µg/Actuation), 2 Inhalations b.i.d., on Parameters of Small Airway Function in Patients With Chronic Obstructive Pulmonary Disease.
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 入组人数
- 113
- 试验地点
- 1
- 主要终点
- Change from baseline to end of treatment in post-dose residual volume.
研究概览
简要总结
The purpose of the present study is to demonstrate the higher efficacy of small particles Foster® 100/6 (two puffs b.i.d.) versus large particles Symbicort® 200/6 (two inhalations b.i.d.), in terms of residual volume reduction over a 12-week treatment period in Chronic Obstructive Pulmonary Disease (COPD) patients.
详细描述
Chronic obstructive pulmonary disease (COPD) is an incurable, debilitating and progressive disease that can be fatal. The recent Global Burden of Disease Study ranks COPD as the 6th leading cause of mortality and the 12th leading cause of morbidity world-wide. Furthermore, trends in the use of medical care resources indicate that the economic cost of COPD continues to rise in direct relation to the ageing population, the increase in prevalence of disease and the cost of new and existing medical and public health interventions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female patients aged ≥ 40 years, who have signed an Informed Consent form prior to initiation of any study-related procedure or when applicable written informed consent obtained by legal representative.
- •Outpatients with a clinical diagnosis of moderate to severe COPD and including:
- •Smoking history of at least 10 pack years defined as [(number of cigarettes smoked per day) x (number of years of smoking)] / 20, both current and ex-smokers are eligible.
- •Regular use of bronchodilators (e.g. β2-agonist, anticholinergics) in the 2 months before visit
- •Post-bronchodilator FEV1 < 65% of the predicted normal value at visit
- •Post-bronchodilator FEV1/FVC < 0.7 at visit
- •An increase in FEV1 < 15% and < 200 mL from baseline following administration of 400 µg of salbutamol at visit
- •Plethysmographic Functional Residual Capacity (FRC) > 120% of the predicted normal value (at visit 1 and visit 2).
- •A Baseline Dyspnoea Index (BDI) focal score less or equal to 10 (at visit 1 and at visit 2).
- •A cooperative attitude and ability to be trained to the proper use of pMDI and DPI (Turbohaler®, inspiratory flow-driven, multidose powder inhaler) inhalers.
排除标准
- •Diagnosis of asthma or other clinically or functionally relevant respiratory disorders (other than COPD) which may interfere with data interpretation according to the investigator's opinion.
- •Clinically unstable concurrent disease: e.g. hyperthyroidism, diabetes mellitus or other endocrine disease; significant hepatic impairment; significant renal impairment; cardiovascular disease (e.g. coronary artery disease, hypertension, heart failure); gastrointestinal disease (e.g. active peptic ulcer); neurological disease; haematological disease; autoimmune disorders, or other which may impact the evaluation of the results of the study according to investigator's judgement.
- •Patients with COPD exacerbation and/or symptomatic infection of the airways requiring antibiotic therapy (at least 5 days) in the 2 months prior to screening and during the study period.
- •Patients treated with depot corticosteroids in the 2 months preceding the visit 1 and during the run-in period.
- •Major surgery in the previous 3 months and during the trial which may affect patient's compliance in study procedures (e.g. plethysmography).
- •Patients requiring chronic mechanical ventilation for COPD.
研究组 & 干预措施
Foster®
Foster® (beclomethasone dipropionate 100 µg plus formoterol 6 µg/unit dose), 2 inhalations b.i.d. (daily dose of BDP "extrafine" 400 µg plus FF 24 µg).
干预措施: Foster® 100/6 µg/unit dose (Drug)
Symbicort® Turbohaler®
Symbicort® Turbohaler® (budesonide 200 μg plus formoterol fumarate 6 μg/actuation), 2 inhalations b.i.d. (daily dose of BUD 800 μg plus FF 24 μg).
干预措施: Symbicort® Turbohaler® 200/6 μg/actuation (Drug)
结局指标
主要结局
Change from baseline to end of treatment in post-dose residual volume.
时间窗: At day 84
次要结局
- Changes from baseline in FEV1, FVC, FEV1/FVC, IVC/FVC, RV, TLC, RV/TLC, FRC, FRC/TLC, RV/VC, Raw, eff and sGaw, eff.(At day 84)
- Changes from baseline in airways resistance (R5, R20, R5-20) and reactance at 5 Hertz (X5) (in a subset of at least 50% of patients from pre-selected sites);(at day 84)
- Changes from baseline in COPD symptom scores (for each single score and the total score);(At day 84)
- Change from baseline in percentage of COPD symptom-free days;(At day 84)
- Change from baseline in rescue salbutamol or ipratropium bromide consumption (puffs per day);(At day 84)
- Change from baseline in percentage of rescue salbutamol or ipratropium bromide-free days;(At day 84)
- Transition Dyspnoea Index (TDI) score;(At day 84 (V4))
- Clinical COPD Questionnaire (CCQ);(At screening (day -28), at baseline (day 0) and at the end of trial (day 84))
- Physical activity (by means of pedometer);(Each day of the two weeks before each clinic visit)
- Nasal brushing (mRNA expression);(At screening (day -28), at baseline (day 0) and at the end of trial (day 84))
- Number of patients with COPD exacerbations.(From pre-screening (day -35) to the end of trial (day 84))